The MLL says Thank You

Dear friends and colleagues,

As this very unusual year is now drawing to its end,we have all come to realize, both in our professional and private lives, that plans and goals are only relative. It has also become quite apparent how medicine can profoundly impact our daily lives and actions.

This is why the MLL, just like you, had to embrace the precise meaning of being "system relevant". We considered it our top priority to provide you with the very best care, as effectively as possible, and better than ever before, in the best interest of your patients.

Our team has stood by us in a truly unique way, and we are very impressed by the commitment each and every team member has demonstrated to fulfill this duty in the interests of the patients concerned.

During this process, we have come to realize more than ever before that digitalization, automation and the ability to rapidly advance projects, from data processing and transmission to the implementation of artificial intelligence in research and in routine, are key assets and will be even more so in the future.

We have also identified that there is room and there are opportunities for improvement in all of these areas of collaboration, and we are now sincerely inviting your constructive feedback, both for now and for the coming year ahead.

In the interests of all of our patients, we have also endeavored to make all of our existing science-based understanding for the future of leukemia diagnostics available in the form of lectures and publication to all potential users. With this in mind in particular, we wish to extend our thanks both to you and your patients for your great willingness to provide patient samples and, above all, information on therapy and outcome within the scope of scientific collaborations. We sincerely appreciate your support and will make every effort to be mindful of the time you are devoting to provide this resource.

The current year has not only demonstrated that science-based collaborations are of fundamental importance to us all well beyond their direct benefits to our hematology and oncology patients,but has also made us intensely aware of how vulnerable seemingly stable systems really are and an appreciation that our patients face such challenges every day as part of their diagnosis and therapy.

Our future capabilities and plans are designed to provide you with patient-centered diagnostics and targeted therapy recommendations, based on scientific principles and prognostic information in a timely manner.

We thank you for your trust in us and look forward to our ongoing collaboration!

With kind regards and all our best wishes for a peaceful holiday season and a wonderful, prosperous and as yet untold 2021

Claudia Haferlach                                     
Torsten Haferlach                                         
Wolfgang Kern

The author

»Do you have questions regarding this article or do you need further information? Please send me an e-mail.«

Prof. Dr. med. Dr. phil. Torsten Haferlach

Executive management
Internist, Hematologist and Oncologist
Deputy Head of Cytomorphology

T: +49 89 99017-100